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Abstract: This study aims to inform SARS-CoV-2 vaccine development/licensure/decision
-making/implementation, using mathematical modeling, by determining key preferred vaccine
product characteristics and associated population-level impacts of a vaccine eliciting long-term
protection. A prophylactic vaccine with efficacy against acquisition (VES) ≥70% can eliminate the
infection. A vaccine with VES <70% may still control the infection if it reduces infectiousness or
infection duration among those vaccinated who acquire the infection, if it is supplemented with <20%
reduction in contact rate, or if it is complemented with herd-immunity. At VES of 50%, the number of
vaccinated persons needed to avert one infection is 2.4, and the number is 25.5 to avert one severe
disease case, 33.2 to avert one critical disease case, and 65.1 to avert one death. The probability of
a major outbreak is zero at VES ≥70% regardless of the number of virus introductions. However,
an increase in social contact rate among those vaccinated (behavior compensation) can undermine
vaccine impact. In addition to the reduction in infection acquisition, developers should assess the
natural history and disease progression outcomes when evaluating vaccine impact.
Keywords: SARS-CoV-2; COVID-19; coronavirus; epidemiology; vaccine; mathematical model
1. Introduction
Following the Severe Acute Respiratory Syndrome (SARS) epidemic in 2002 and the Middle East
Respiratory Syndrome (MERS) epidemic in 2012 [1], a novel coronavirus, the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), emerged in late December 2019 in Wuhan, Hubei province,
China [2,3]. While the earlier coronavirus epidemics were rather limited in scope and scale [1],
SARS-CoV-2 rapidly spread [4] and evolved into a pandemic [5].
In the absence of an even partially efficacious vaccine [6], containment of the epidemic in China
necessitated large-scale contact tracing and testing through the deployment of thousands of healthcare
fieldworkers along with severe quarantine measures [4]. The strain put on healthcare systems [7]
and the global human [8,9] and economic [10] losses caused by the virus and the resulting disease,
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designated as Coronavirus Disease 2019 (COVID-2019) [11], accelerated efforts towards vaccine
development [6,12]. While multiple vaccine candidates are currently in the pipeline, they are still in
the early stages of development [6,12,13].
Assessment of the population-level impact of vaccine candidates through mathematical modeling
is a critical component in the process of vaccine development, value proposition, licensure,
decision-making, and pathways and costs of vaccine administration and has been utilized for
a wide range of infectious diseases [14–28]. In the early stages of development, modeling is
used to define the vaccine’s key preferred product characteristics by estimating levels of efficacy
necessary to observe a significant population-level impact, determining the necessary duration
of protection/immunity incurred by the vaccine, and identifying priority populations for optimal
effectiveness [21,29,30]. These parameters provide early guidance to developers, manufacturers,
regulators, and decision-makers about candidates that are likely to be optimal through specifying
vaccine characteristics that will maximize public health impact and cost-effectiveness [21,28,29,31,32].
Once key attributes are established, modeling plays an integral role in building the case for investment
in vaccine development, and in ensuring rapid roll-out post-licensing, through assessment of risks,
costs, and predicted returns associated with different immunization strategies [29,33]. Post-vaccination,
modeling is used to inform the design and interpretation of surveillance studies [25–27].
We aimed in this study to provide the scientific evidence necessary to inform and accelerate
SARS-CoV-2 vaccine development, licensure, decision-making, and implementation by determining
key preferred vaccine product characteristics and associated population-level impact, at a critical time
for such development [6,12,13]
2. Materials and Methods
2.1. Mathematical Model
A deterministic model was constructed to describe SARS-CoV-2 transmission dynamics in a
given population, namely China as an illustrative example, in the presence of vaccination (Figure S1).
The model extended a recently developed age-structured model focused on analyzing SARS-CoV-2
epidemiology in China [34]. The model’s structure was informed by current understanding of
SARS-CoV-2′s natural history and epidemiology and consisted of a set of coupled nonlinear differential
equations that stratified the population into compartments based on vaccination status, age group,
infection status, infection stage, and disease stage (Text S1A). Vaccine impact was assessed over the
course of one epidemic cycle, and the population was assumed to be stable with no births introduced.
The developed model was informed by existing literature on the direct and indirect effects of vaccination
such as vaccine impact on epidemic size, critical vaccination threshold, and effectiveness, assuming
different types of vaccine efficacy [35–40]. The latter includes, in addition to the classical efficacy
against susceptibility, efficacies against infectiousness and disease progression (Table 1) [35–40].
For both vaccinated and unvaccinated populations, nine age groups were considered, each
representing a 10-year age band except for the last category (0–9, 10–19, . . . , ≥80 years).
Susceptible individuals were at risk of being exposed to the infection at varying hazard rates depending
on their age group and vaccination status. Following a latency period, infected individuals develop
asymptomatic or mild infection followed by recovery, or severe infection followed by severe disease
and then recovery, or critical infection followed by critical disease and either recovery or disease
mortality. Mixing between individuals of different age groups was determined by an age-mixing
matrix that allows a range of mixing (Text S1). The level of assortativeness in mixing between the
different age groups was determined by a parameter whose value was set based on an earlier study
that indicated limited assortativeness in mixing by age in the original Wuhan outbreak in China [34].
Details on model structure are in Supplementary Material. The model was coded, fitted, and analyzed
using MATLAB R2019a [41].
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Table 1. Key vaccine product characteristics used to assess impact of a vaccine against SARS-CoV-2.
Vaccine Characteristic Definition Description
VES
Vaccine efficacy in reducing
susceptibility
Proportional reduction in the
susceptibility to infection acquisition
among those vaccinated compared to
those unvaccinated
VEI
Vaccine efficacy in reducing
infectiousness
Proportional reduction in infectiousness
(lower viral load due to vaccine-primed
immune response) among those who are
vaccinated but acquire the infection
compared to those unvaccinated
VEP1
Vaccine efficacy in reducing the
duration of infection
Proportional reduction in the duration of
mild infection (faster infection clearance
due to vaccine-primed immune response)
among those who are vaccinated but still
acquire the infection compared to those
unvaccinated
VEP2
Vaccine efficacy in reducing the
fraction of individuals with severe
or critical infection
Proportional reduction in the fraction of
individuals with severe or critical
infection (lower probability of developing
severe or critical infection due to
vaccine-primed immune response) among
those who are vaccinated but still acquire
the infection compared to those
unvaccinated
D Duration of vaccine protection Duration of protection that the vaccinewill elicit
r Behavior compensationpost-vaccination
Proportional increase in social contact rate
(reduced social distancing) among those
who are vaccinated compared to
those unvaccinated
2.2. Model Parameterization and Fitting
The model was parameterized and calibrated using empirical data on SARS-CoV-2′s natural
history and epidemiology. Age-specific distributions of infected individuals across the mild, severe, or
critical infection stages were based on case-severity levels observed in China [4,42,43]. Critical disease
cases were at risk of disease mortality, with the relative mortality rate in each age group informed
by the age-specific crude case fatality rate observed in China [3,44]. Population size, demographic
structure (age distribution), and life expectancy, as of 2020, were obtained from the United Nations
World Population Prospects database [45]. The model was fitted to empirical time series data for the
daily and cumulative numbers of diagnosed SARS-CoV-2 cases and deaths [46], number of recovered
individuals [46], and the age-specific attack rate [44,47]. Details of model parameters, values, and
justifications are in Tables S1 and S2 and Text S1B,C.
2.3. Product Characteristics of Candidate Vaccines
We assessed the impact of a prophylactic vaccine that reduces susceptibility to infection. However,
since the first available vaccine may only be partially efficacious against infection acquisition, we also
assessed the impact of the vaccine assuming additional “breakthrough” effects, that is, effects that
modulate the natural history of infection for those who are vaccinated but still acquire the infection.
Specifically, we assumed that vaccination may reduce infectiousness per one contact (by reducing
viral load), infection duration (by faster clearance with vaccine-induced immunity), and likelihood of
developing severe or critical disease (by rapid immune response that prevents disease progression).
Definitions of these vaccine efficacies are summarized in Table 1.
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Other relevant characteristics include the duration of protection elicited by the vaccine and
vaccination effect on adherence to social distancing; we investigated the impact of increasing social
contact rate following vaccination with the perception of protection.
2.4. Measures of Vaccine Impact
The population-level impact of SARS-CoV-2 vaccination was assessed by quantifying incidence,
cumulative incidence, and reduction in the incidence of infections, severe disease cases, critical
disease cases, and deaths arising in the presence of vaccination compared to the counterfactual
scenario of no-vaccination. Vaccination impact was further assessed by quantifying effectiveness,
which is the number of vaccinated persons needed to avert one infection or one adverse disease
outcome (ratio of number of vaccinations relative to that of averted outcomes). The latter measure
is essentially cost-effectiveness, with no costs included as they are not yet available, and is therefore
likely to be influential in informing vaccine prioritization to different segments of the population
such as individuals in different age groups. Vaccination impact was assessed at: (1) VES = 50%
but VEI = VEP1 = VEP2 = 0%, (2) VEI = 50% but VES = VEP1 = VEP2 = 0%, (3) VEP1 = 50%
but VES = VEI = VEP2 = 0%, (4) VEP2 = 50% but VES = VEI = VEP1 = 0%, and (5) VES =
VEI = VEP1 = 50%. Vaccine was assumed to elicit protection over 10 years, with this duration being
exponentially distributed.
2.5. Vaccination Program Scenarios
Two vaccination program scenarios were considered. In both programs, it was assumed that
vaccination is introduced in the absence of social-distancing interventions, as the purpose of vaccination
is to replace such interventions. The first program scenario assumes vaccine introduction and scale-up
to 80% coverage before epidemic onset. This scenario is relevant for assessing the impact of vaccination
on future SARS-CoV-2 introductions in countries where the epidemic has been contained or at a
low level, such as in China. The scenario is also relevant to assess the maximum potential impact of
vaccination regardless of current epidemic status. The second program scenario assumes vaccine
introduction during the epidemic’s exponential growth phase, with scale-up to 80% coverage within
one month.
2.6. Additional Analyses
Incidence of new infections was assessed at various levels of VES to determine the minimum
efficacy needed to fully control the infection, that is, to reach a negligible incidence level (end of epidemic
cycle), if not complete elimination. Incidence was also assessed in a scenario where vaccination was
introduced with a social-distancing intervention to estimate the level of social distancing needed to
complement vaccination to control the infection. Incidence was assessed in another scenario where
those vaccinated increased their social contacts (behavior compensation), to assess consequences on
vaccination impact. Lastly, we derived and estimated the likelihood of the occurrence of a major
outbreak following infection introduction in a vaccinated but infection-free population (Text S1D).
In addition, two sensitivity analyses were conducted to assess vaccine effectiveness at varying
levels of vaccine coverage and at high levels of assortativeness in age group mixing.
2.7. Uncertainty Analysis
A multivariable uncertainty analysis was conducted to determine the range of uncertainty around
model predictions using five hundred model runs. At each run, Latin Hypercube sampling [48,49] was
applied in selecting the natural history and disease progression parameter values from ranges specified
by assuming ±30% uncertainty around parameters’ point estimates. The model was then refitted to
input data and vaccine impact assessed in the new fitted model. The resulting distribution for vaccine
impact across all 500 runs was used to calculate predicted means and 95% uncertainty intervals (UIs).
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3. Results
Figures 1 and 2 illustrate the impact of vaccination assuming different vaccine product
characteristics (efficacies; described in Table 1) for each vaccination program roll-out scenario (see
Section 2 for details). In the first scenario (Figure 1 and Figures S2 and S3), where vaccination was
scaled up to 80% coverage before epidemic onset, the epidemic in absence of vaccination peaked at
158 days after virus introduction but at 286 days when VEP1 = 50%, 452 days when VEI = 50%, and
462 days when VES = 50%. There was no epidemic when VES = VEI = VEP1 = 50%. A vaccine with
VES = 50% reduced peak infection incidence by 84.4% and cumulative/total infections by 52.8%, peak
severe disease incidence by 83.9% and cumulative severe disease cases by 53.4%, peak critical disease
incidence by 82.1% and cumulative critical disease cases by 46.7%, and peak death incidence by 79.0%
and cumulative deaths by 44.4%. A vaccine with VEI = 50% yielded slightly lower reductions in the
incidence of infection and adverse outcomes, while a vaccine with VEP1 = 50% was less impactful
but still achieved considerable reductions. A vaccine with VEP2 = 50% had no impact on infection
incidence, but reduced peak incidence of each of severe and critical disease by 38.5% and deaths by
40.0% (Figure 1), and the cumulative incidence of the latter three outcomes by ~39% (Figures S2 and S3).
Figure 1. Impact of SARS-CoV-2 vaccination on the number of (A) new infections, (B) new severe
disease cases, (C) new critical disease cases, and (D) new deaths in the scenario assuming vaccine
scale-up to 80% coverage before epidemic onset. The duration of vaccine protection is 10 years. Impact
was assessed at VES = 50%, VEI = 50%, VEP1 = 50%, VEP2 = 50%, VES = VEI = VEP1 = 50%.
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Figure 2. Impact of SARS-CoV-2 vaccination on the number of (A) new infections, (B) new severe
disease cases, (C) new critical disease cases, and (D) new deaths in the scenario assuming vaccine
introduction during the exponential growth phase of the epidemic, with scale-up to 80% coverage
within one month. Duration of vaccine protection is 10 years. Impact was assessed at VES = 50%,
VEI = 50%, VEP1 = 50%, VEP2 = 50%, VES = VEI = VEP1 = 50%.
In the second scenario (Figure 2 and Figures S4 and S5), where vaccination was rapidly scaled
up to 80% coverage during the exponential growth phase, the epidemic peaked earlier and at lower
values for incidence of infection and adverse outcomes. The impact of a vaccine with VES = 50% was
initially similar to that of a vaccine with VES = VEI = VEP1 = 50%; however, over time, the latter was
more impactful in reducing infection and adverse outcomes. Reduction in the cumulative number
of new infections (at end of epidemic cycle) was highest for VES = VEI = VEP1 = 50% at 53.4%,
followed by VES = 50% at 41.2%, VEI = 50% at 28.2%, and VEP1 = 50% at 23.1%, with no reduction
for VEP2 = 50%. Reduction in cumulative number of new deaths for these efficacies was, respectively,
47.2%, 34.8%, 22.5%, 18.0%, and 30.0%.
Figure 3 illustrates vaccine effectiveness in averting infection and adverse outcomes by the end
of the epidemic cycle (that is, after the epidemic has reached its peak and declined to a negligible
level) for the first program scenario. For VES = 50%, 2.4 vaccinated persons were needed to avert one
infection, 25.4 to avert one severe disease case, 33.2 to avert one critical disease case, and 65.1 to avert
one death. Effectiveness was nearly comparable for VEI = 50%, whereas more vaccinated persons
were needed to avert one infection or one adverse outcome for VEP1 = 50% and VEP2 = 50%. The best
effectiveness was for VES = VEI = VEP1 = 50% where only 1.3 vaccinated persons were needed to
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avert one infection, 13.6 to avert one severe disease case, 15.5 to avert one critical disease case, and
28.9 to avert one death. Graphs illustrating temporal evolution of vaccine effectiveness for vaccination
program scenarios 1 and 2 are shown in Figures S6 and S7, respectively.
Figure 3. SARS-CoV-2 vaccine effectiveness. Number of vaccinated persons needed to avert (A) one
infection, (B) one severe disease case, (C) one critical disease case, and (D) one death, by the end of
the epidemic cycle, that is, after the epidemic has reached its peak and declined to a negligible level.
The scenario assumes vaccine scale-up to 80% coverage before epidemic onset. Duration of vaccine
protection is 10 years. Impact was assessed at VES = 50%, VEI = 50%, VEP1 = 50%, VEP2 = 50%,
VES = VEI = VEP1 = 50%. Panel A does not include the result for VEP2 = 50%, as this efficacy has no
impact on the number of infections—it affects only severe and critical disease and death.
Figure 4 shows the effectiveness of age-group prioritization by the end of the epidemic cycle
using a vaccine introduced before epidemic onset with VES = 50%. Prioritizing adults ≥20 years
of age was most effective in reducing infection incidence. By prioritizing each age group ≥20 years
of age, ≤3 vaccinated persons were needed to avert one infection. By vaccinating the entire age
bracket of those who are ≥20 years of age, 2.4 vaccinated persons were needed to avert one infection.
Meanwhile, prioritizing adults ≥60 years of age was most effective in reducing new deaths, with ≤36
vaccinated persons needed to avert one death. Prioritizing children was least effective, with a large
number of vaccinated persons needed to avert one infection or one adverse outcome. Note that there
are minor differences in effectiveness over time. For instance, in the initial phases of the epidemic,
prioritizing those 60–69 years of age was slightly more effective than prioritizing those 40–49 years of
age (Figure S8). Meanwhile, towards the end of the epidemic cycle, the inverse was true.
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Figure 4. Effectiveness of age-group prioritization using a SARS-CoV-2 vaccine with VEs of 50%.
Number of vaccinated persons needed to avert (A) one infection, (B) one severe disease case, (C) one
critical disease case, and (D) one death by prioritizing different age groups for vaccination. Scenario
assumes vaccine scale-up to 80% coverage before epidemic onset and duration of vaccine protection
of 10 years. Effectiveness is assessed at the end of the epidemic cycle, that is, after the epidemic has
reached its peak and declined to a negligible level.
Figure 5 shows cumulative number of infections, which is the final epidemic size at the end of
the epidemic cycle at various VES levels for a vaccine introduced before epidemic onset. A gradual
decrease is observed as VES increases, with an accelerated reduction as VES approaches 60%—the level
beyond which the number of infections approaches zero. Epidemic onset is prevented at VES = 69%.
Figure 5B illustrates the gains in effectiveness as VES increases, with 5.3 vaccinated persons needed to
avert one infection at VES = 30%, but only 1.3 at VES = 60%.
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Figure 5. Impact of varying levels of vaccine efficacy in reducing susceptibility (VEs) on (A) cumulative
number of new SARS-CoV-2 infections (final epidemic size) and (B) number of vaccinated persons
needed to avert one SARS-CoV-2 infection. Scenario assumes vaccine scale-up to 80% coverage before
epidemic onset. Duration of vaccine protection is 10 years. Measures are assessed at the end of the
epidemic cycle, that is, after the epidemic has reached its peak and declined to a negligible level.
While a vaccine with VES = 50% cannot fully control the epidemic, Figure S9 shows the impact
when vaccination is supplemented with a social-distancing intervention that reduces the contact rate.
A reduction in contact rate less than 20% would be sufficient to fully control the epidemic.
Vaccinated individuals may increase their contact rate with the perception of protection. Figure 6
shows the consequences of behavior compensation. A 20% increase in contact rate among those
vaccinated lowers the reduction in cumulative incidence from 52.8% to only 21.0%. A 41.8% increase
in contact rate nullified the impact of vaccination in reducing incidence.
Vaccines 2020, 8, 668 10 of 16
Figure 6. Impact of vaccination with reduced adherence to social distancing for those vaccinated. Figure
shows the impact of varying levels of behavior compensation post-vaccination on the vaccine-induced
reduction in the cumulative number of new SARS-CoV-2 infections by the end of the epidemic cycle.
Scenario assumes vaccine scale-up to 80% coverage before epidemic onset, VEs is 50%, and duration of
vaccine protection is 10 years.
Figure 7 reports the probability of occurrence of a major outbreak at varying levels of vaccine
efficacy. A gradual decrease is noted with the increase in efficacy that accelerates close to VES or VEI of
~70%, VEP1 of ~85%, and VES = VEI = VEP1 of ~33%, beyond which no major outbreak is expected
to occur. Note that this figure shows (conservatively) the upper bound of the probability of a major
outbreak. Results for the lower bound are in Figure S10.
Our sensitivity analyses showed that effectiveness was not strongly dependent on vaccine coverage
(Figure S11A), but that high assortativeness in age group mixing would result in considerably more
vaccinations needed to avert one infection among children while not substantially affecting effectiveness
in the older age groups (Figure S11B).
Uncertainty analysis demonstrated robustness of model predictions to a wide range of uncertainty
in input parameters (Figure S12).
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Figure 7. Probability of occurrence of a major outbreak following vaccination. Probability of occurrence
of a major outbreak upon virus introduction at varying levels of (A) VES, (B) VEI, (C) VEP1 , and
(D) VES = VEI = VEP1 . Scenario assumes vaccine scale-up to 80% coverage before epidemic onset.
Duration of vaccine protection is 10 years. The figure does not include the result for VEP2 , as this efficacy
has no impact on the probability of occurrence of a major outbreak. The analysis and derivation for the
probability of occurrence of a major outbreak can be found in Text S1D of the Supplementary Material.
4. Discussion
The above results indicate that even a partially efficacious vaccine can offer a fundamental
solution to the SARS-CoV-2 pandemic—the vaccine does not need to have sterilizing immunity to fully
control the infection. Indeed, a vaccine with VES ≥70% could be sufficient to control the pandemic
at ≥80% coverage (Figure 5A). Even a vaccine with VES <70% may still control the infection if it
additionally (and plausibly) induces “breakthrough” effects such as reduction in viral load (reduction
in infectiousness; VEI) or faster infection clearance (reduction in infection duration; VEP1 ) among those
vaccinated who still acquire the infection. The latter effects individually (that is, in absence of protection
against acquisition) have a comparable impact on transmission to that of a prophylactic vaccine that
reduces infection acquisition (Figures 1 and 2). Even in the absence of such effects, infection control can
still be achieved if vaccination is supplemented with only a moderate social-distancing intervention
(Figure S9) or complemented with partial herd immunity—a considerable fraction of the population
could have acquired the infection and developed protective antibodies by the time of vaccine roll-out.
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Even a vaccine that does not prevent infection yet only mitigates disease progression (reduction in
severe or critical disease and death; VEP2 ) could still yield significant gains by curbing disease burden
(Figures 1 and 2).
Results also indicated that vaccine impact depends on the time of vaccine introduction, whether
before (Figure 1 and Figures S2 and S3) or after (Figure 2 and Figures S4 and S5) epidemic onset
and/or growth; maximal gains are achieved with earlier introduction. Early introduction optimally
defers epidemic growth, flattens the incidence curve, and reduces the number of infections and disease
outcomes (Figure 1, Figure 2 and Figures S2–S5).
The vaccine will likely be cost-effective over a broad range of efficacy levels (Figure 5B). For a
vaccine with VES of 50%, the number of vaccinations needed to avert one infection is only 2.4, 25.5
are needed to avert one severe disease case is, 33.2 to avert one critical disease case, and 65.1 to avert
one death (Figure 3). Return on effectiveness is also rapid for such a respiratory infection with a
fast-growing epidemic scale (Figures S6 and S7).
Effectiveness can be further enhanced by prioritizing vaccination for those ≥60 years of age
for an optimal reduction in disease cases and deaths (Figure 4). Conversely, prioritizing children is
least effective, with their lower risk for developing adverse outcomes [4,50,51] (Figure 4). This being
said, prioritizing vaccination for any single age group, regardless of age group, has overall lower
effectiveness than extending vaccination to all age groups—vaccinating only one age group reduces
the reproduction number (R0) only marginally, whereas vaccinating all age groups reduces R0 to an
epidemic domain where small reductions in R0 can have a more substantial impact on epidemic size
(Figure S13, also Figure 3 versus Figure 4). Consequently, roll-out strategies should initially prioritize
individuals ≥60 years of age but then incrementally cover younger age cohorts and eventually the
entire population.
Vaccination will also reduce the likelihood of a major outbreak following virus
introduction/reintroduction into a population (Figure 7). With a vaccine of VES ≥70%, infection
transmission chains may not be sustainable, regardless of the number of virus introductions. Of concern,
however, is the potential increase in social contact rate among those vaccinated (behavior compensation):
a 42% increase in contact rate can virtually nullify the gains of a vaccine with VES of 50% at a coverage
of 80% (Figure 6). Roll-out of a vaccine with intermediate efficacy should be coupled with public health
communication that stresses caution in social mixing following vaccination.
This study has limitations. Model estimations are contingent on the validity and generalizability
of input data. While we used available evidence for SARS-CoV-2 natural history and epidemiology,
our understanding of its epidemiology is still evolving. We assessed vaccine impact using China as an
illustrative example, where the outbreak first emerged, yet evidence suggests that many infections
may have been undocumented in this country, particularly in the early epidemic phase [52]. This may
affect some estimates, such as mortality, probably towards overestimation [34,53]. While the absolute
impact of the vaccine on disease severity and mortality may have been overestimated, the relative
impact (reduction rate) is less likely to have been affected. Our baseline R0 for China was 2.1 [34],
but R0 may vary across settings as suggested by existing evidence [54,55], thus affecting estimates for
the minimum efficacy or the minimum coverage needed for infection elimination. For instance, for an
R0 of 3, the minimum VES needed for elimination is about 90% (Figure S14). Similarly, higher vaccine
coverage levels will be needed to achieve elimination at higher values of R0. We assessed vaccine
impact in a country with limited infection spread relative to population size, but future work will
need to factor differences in the epidemic phase in modeling assessments of vaccine impact in other
countries. We also assessed vaccine impact for one epidemic cycle, with no assessment of seasonality
or future cycles. Assessment of the long-term impact of vaccination will require an extension of the
model to factor in the waning of natural immunity among recovered individuals; rapid waning of
natural immunity or vaccine immunity will require more and repeat vaccinations. We assumed a
long duration of vaccine protection (10 years), but this has limited impact on the predictions for one
epidemic cycle, provided the duration of vaccine protection is greater than one year. Despite these
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limitations, our model was complex enough to factor the different key vaccine product characteristics
but also parsimonious enough to be tailored to the nature of available data. The model also generated
results that are valid to a wide range of model assumptions.
5. Conclusions
With most of the world’s population remaining susceptible to SARS-CoV-2 and the need to
impose disruptive social-distancing interventions, vaccination is a reliable intervention in the long
term. Findings show that even a partially efficacious vaccine provides a fundamental solution to
the SARS-CoV-2 pandemic and at high cost-effectiveness. Vaccine impact and cost-effectiveness will
not only depend on its efficacy in preventing infection but can be enhanced if those vaccinated who
still acquire the infection have reduced infectiousness, duration of infection, and disease severity.
Vaccine developers should thus not only assess the primary endpoint of reduction in acquisition but
also other outcomes and/or proxy biomarkers including reductions in viral load and disease outcomes
and speed of infection clearance for those vaccinated and unvaccinated. The totality of these primary
and secondary endpoints may prove critical in the licensure process, decision-making, and vaccine
impact once introduced into a population.
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